2017 Preliminary Program

PRELIMINARY PROGRAM
Working titles/topics shown. Final titles and speakers will follow.

EDUCATIONAL SESSIONS

Tuesday, December 5, 2017

Most of the presentations at SABCS focus on the latest clinical and basic research results relating to breast cancer. By contrast, educational sessions are designed to inform and update those interested in a review on a particular topic. Although these sessions may include new specific research findings, their primary intent is to offer summaries of existing knowledge, and to provide background for some of the active areas which will be discussed in the rest of the meeting.

Changing Recommendations for Intermediate Risk Lesions
Moderator: Virginia G. Kaklamani, MD
UT Health San Antonio
San Antonio, TX

The pathology of high risk proliferative lesions of the breast
Kalliopi P. Siziopikou, MD, PhD
Northwestern University
Chicago, IL

Managing increased breast cancer risk based on high and moderate penetrance gene mutations
Judy E. Garber, MD, MPH
Dana-Farber Cancer Institute
Boston, MA

Clinical management of women with increased breast cancer risk based on histologic lesions
Amy C. Degnim, MD
Mayo Clinic
Rochester, MN

Androgen, Progesterone and Glucocorticoid Receptors: Drivers of Breast Tumor Progression or Reprogramming of Steroid Receptors During Breast Tumor Progression
Moderator: Suzanne A.W. Fuqua, PhD
Baylor College of Medicine
Houston, TX

Role of androgen receptors in both estrogen receptor positive and negative breast cancer
Jennifer K. Richer, PhD
University of Colorado
Aurora, CO

Tracking progesterone receptor actions in breast cancer progression: Jekyll and Hyde
Carol A. Lange, PhD
University of Minnesota
Minneapolis, MN

Modulating glucocorticoid receptor function in breast cancer 
Suzanne D. Conzen, MD
The University of Chicago
Chicago, IL

Medical Treatment of HER2+++ Breast Cancer
Moderator: Angelo Di Leo, MD, PhD
Hospital of Prato
Prato, ITALY

Her2 testing - 2017 guidelines for HER2 testing
Robert B. Jenkins, MD, PhD
Mayo Clinic
Rochester, MN

Adjuvant HER2+
Ruth M. O'Regan, MD
University of Wisconsin
Madison, WI

Can we improve treatment tailoring in advanced HER2+ breast cancer? 
Martine J. Piccart, MD, PhD
Universite Libre de Bruxelles
Brussels, BELGIUM

Management Controversies in Locoregional Recurrence
Moderator: Irene Wapnir, MD
Stanford Women's Cancer Center
Stanford, CA

Challenges in the surgical management of locoregional recurrence 
Monica Morrow, MD
Memorial Sloan Kettering Cancer Center
New York, NY

Should all patients with locoregional recurrence receive systemic therapy?
William J. Gradishar, MD
Northwestern University
Chicago, IL

Local regional recurrence
Richard C. Zellars, MD
Indiana University
Indianapolis, IN

Challenges in Advanced/Metastatic Breast Cancer (ABC)
Moderator: Fatima Cardoso, MD
Champalimaud Clinical Centre
Lisbon, PORTUGAL

Introduction: Where there is controversy, let it be guidance
Fatima Cardoso, MD
Champalimaud Clinical Centre
Lisbon, PORTUGAL

Luminal ABC: optimal use of all available options?
Angela M. DeMichele, MD, MSCE
University of Pennsylvania 
Philadelphia, PA

Local therapy of limited disease in ABC: what is the evidence?
Seema A. Khan, SM, MB
Northwestern University
Chicago, IL

Novel technologies to direct therapies in ABC
Fabrice Andre, MD, PhD
Institut Gustave Roussy
Villejuif, FRANCE

Balancing active treatment and palliative care in ABC patients
Thomas J. Smith, MD
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, MD

Shifting Paradigms in Radiation Oncology
Moderator: Richard L. Crownover, MD, PhD
UT Health San Antonio
San Antonio, TX

Accelerated partial breast irradiation: Update of an ASTRO consensus guideline
Candace Correa, MD
Community Cancer Center
Normal, IL

Guidelines for postmastectomy radiotherapy
Abram Recht, MD, FASTRO, FASCO
Beth Israel Deaconess Medical Center
Boston, MA

Advanced technologies to optimize outcomes and minimize toxicities  
Reshma Jagsi, MD, PhD
University of Michigan 
Ann Arbor, MI

Multi-Level Influences on Breast Cancer Disparities
Moderator: Melissa L. Bondy, PhD, MS
Baylor College of Medicine
Houston, TX

Introduction
Melissa L. Bondy, PhD, MS
Baylor College of Medicine
Houston, TX

Place as a cause of breast cancer disparities in Appalachia
Electra D. Paskett, PhD, MSPH
The Ohio State University
Columbus, OH

Biologic, cultural and health systems influences on breast cancer disparities in Latinas 
Amelie G. Ramirez, DrPH
UT Health San Antonio 
San Antonio, TX

Carbon footprint of quality and equity of breast cancer care in France
Roman Rouzier, PhD
Institut Curie
Paris, FRANCE

Biologic and health system determinants of breast cancer disparities in African Americans 
Katherine E. Reeder-Hayes, MD
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, NC

Patient Advocate
TBD

The Breast Tumor Microenvironment: A Target for Therapy
Moderator: Leisha A. Emens, MD, PhD
Johns Hopkins University
Baltimore, MD

How tumor metabolism contributes to the immunosuppressive microenvironment
Jeffrey C. Rathmell, PhD
Vanderbilt University
Nashville, TN

How myeloid cells contribute to the immunosuppressive microenvironment
David G. DeNardo, PhD
Washington University School of Medicine 
St. Louis, MO

Opportunities for immune therapy and prevention
Robert H. Vonderheide, MD, DPhil
University of Pennsylvania
Philadelphia, PA

Circulating Tumor Cells and Liquid Biopsies, Translation to Clinical Practice
Moderator: Matthew Ellis, MD, PhD
Baylor College of Medicine
Houston, TX

Cell free DNA analysis in breast cancer: pitfalls and progress
Shashikant Kulkarni, PhD
Baylor College of Medicine
Houston, TX

Exosome analysis in breast cancer: Clinical translation
Jacqueline Bromberg, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NY

Circulating complexes of stromal and tumor cells in breast cancer metastasis
Dorraya El-Ashry, PhD
University of Miami Miller School of Medicine
Sylvester Comprehensive Cancer Center
Miami, FL

Ex-vivo Modeling of Breast Cancer
Moderator: Carlos L. Arteaga, MD
Vanderbilt University Medical Center
Vanderbilt-Ingram Cancer Center
Nashville, TN

Organoids as a novel platform for breast cancer research
Oded Kopper, PhD
Royal Netherlands Academy of Arts and Sciences (KNAW)
The Hubrecht Institute
Utrecht, THE NETHERLANDS

Breast cancer patient-derived xenografts as models for metastatic progression and therapeutic response
Alana Welm, PhD
University of Utah
Salt Lake City, UT

Genetic dissection of cancer development, therapy response, and resistance in mouse models of breast cancer
Jos Jonkers, PhD
Netherlands Cancer Institute
Amsterdam, NETHERLANDS

Beyond Expression Profiling: RNA Epigenetics
Moderator: Douglas Yee, MD
University of Minnesota
Minneapolis, MN

Drugging protein synthesis in cancer therapy
Robert J. Schneider, PhD
New York University
New York, NY

Targeting RNA splicing in cancer therapy
Stephan Vagner, PhD
Curie Institute
CNRS UMR3348
Orsay, FRANCE

Progress, paradigms, and pathways of long non-coding RNAs in cancer
Liuqing Yang, PhD
UT MD Anderson Cancer Center
Houston, TX

 

Top



William L. McGuire Memorial Lecture

TBD
Richard Peto, FRS
University of Oxford
Oxford, UNITED KINGDOM

AACR Distinguished Lectureship in Breast Cancer Research

Leveraging Preclinical Models of Breast Cancer 
Jeffrey M. Rosen, PhD
Baylor College of Medicine
Houston, TX

AACR Outstanding Investigator Award for Breast Cancer Research, funded by Susan G. Komen®

Susan G. Komen® Brinker Awards

 

Top



Potential of Radiation Therapy to Convert the Tumor Into an In Situ Vaccine
Silvia C. Formenti, MD
Weill Cornell Medical College
New York, NY

Individualizing Management of the Axillary Nodes
Tari A. King, MD
Dana-Farber Cancer Institute
Brigham and Women's Cancer Center
Boston, MA

Advances in the Understanding of Mutational Signatures in Human Cells
Serena Nik-Zainal
Wellcome Trust Sanger Institute
Cambridge, UNITED KINGDOM

Top



Molecular Subtypes and Clinical Ramifications of TNBC
Moderator: Tiffany A. Traina, MD
Memorial Sloan Kettering Cancer Center
New York, NY

Gene expression and clinical implications.  Approach to target discovery
Samuel Aparicio, PhD
The University of British Columbia
Vancouver, BC CANADA

New clinical approaches for TNBC
Melinda Telli, MD
Stanford University School of Medicine
Stanford, CA

Lobular Breast Cancer - Is it a Different Disease?
Moderator: Otto Metzger, MD
Dana-Farber Cancer Institute
Boston, MA

Pathology and genomics of lobular breast carcinomas and their precursors
Jorge S. Reis-Filho, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NY

Understanding the unique biology of ILC
Steffi Oesterreich, PhD
University of Pittsburgh
Pittsburgh, PA

Tailoring systemic therapy for patients with lobular breast cancer
Marco A. Colleoni, MD
European Institute of Oncology
Milano, ITALY

Top


Saturday, December 9, 2017

Moderator: C. Kent Osborne, MD
Baylor College of Medicine
Houston, TX

Basic science
Ramon Parsons, MD, PhD
Icahn School of Medicine at Mount Sinai
New York, NY

Translational research
Nicholas C. Turner, BM BCH MRCP PHD FRCP
The Institute of Cancer Research
London, UNITED KINGDOM

Early breast cancer in review
Antonio C. Wolff, MD
Johns Hopkins University
Baltimore, MD

Advanced and metastatic breast cancer
Nancy Lin, MD
Dana-Farber Cancer Institute
Boston, MA

Top



Intratumoral Heterogeneity:  Clinical Implications from Basic Science
Moderator: Elaine Mardis, PhD
Nationwide Children's Hospital
Columbus, OH

Manifestations and implications of subclonal alterations in metastatic breast cancer
Sarat Chandarlapaty, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NY

Breast cancer heterogeneity landscapes
Carlos Caldas, MD
University of Cambridge 
Cambridge, UNITED KINGDOM

Targeting the Tumor Immune Microenvironment
Moderator: Xiang Zhang, PhD
Baylor College of Medicine
Houston, TX

TBD
Cynthia A. Zahnow, PhD
Johns Hopkins Medicine
Baltimore, MD

Myeloid-derived suppressor cells: many facets of regulation of tumor progression
Dmitry Gabrilovich, MD, PhD
The Wistar Institute
Philadelphia, PA

Mechanisms of Early Dissemination and Metastasis
Moderator: TBD

Oncogenic and microenvironmental signals driving early dissemination, dormancy and metastasis
Julio A. Aguirre-Ghiso, PhD
Mount Sinai School of Medicine
New York, NY

The perivascular niche protects dormant disseminated tumor cells from therapy
Cyrus M. Ghajar, PhD
Fred Hutchinson Cancer Research Center
Seattle, WA

Top



Controversies in the Adjuvant Treatment of ER+ Breast Cancer
Moderator: Matthew P. Goetz, MD
Mayo Clinic
Rochester, MN

Adjuvant endocrine therapy for premenopausal ER+ breast cancer
Prudence Francis, MBBS, B Med Sc, FRACP, MD
Peter MacCallum Cancer Centre
Melbourne, AUSTRALIA

Searching for the optimal duration of adjuvant endocrine therapy in breast cancer
Vered Stearns, MD
Johns Hopkins Medicine
Baltimore, MD

Top



Global View of Value Based Medicine
Moderator: Peggy Porter, MD
Fred Hutchinson Cancer Research Center
Seattle, WA

Latin America
Felicia Marie Knaul, PhD
University of Miami
Miami, FL

Middle East
Sana Al Sukhun, MD, MSc
Jordanian Oncology Society
Amman, JORDAN

France HAS
TBD

Top



Molecular Biology in Breast Oncology
Moderator: Carlos L. Arteaga, MD
Vanderbilt University Medical Center
Vanderbilt-Ingram Cancer Center
Nashville, TN

Drug target discovery: how to go about it?
TBD

Bench-based approaches to discover mechanisms of drug resistance (i.e. CRISPR, genome library screens, etc.)
TBD

Genomics & Bioinformatics (big data) in breast cancer research
TBD

Single cell genomics and tumor heterogeneity
Jorge S. Reis-Filho, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NY

Methods in Breast Cancer Clinical Research
Moderator: Virginia G. Kaklamani, MD
UT Health San Antonio
San Antonio, TX

Novel statistical clinical trial designs
TBD

Incorporating biomarkers in clinical trials
Edith Perez, MD
Genentech
South San Francisco, CA

What about neoadjuvant trials and path CR
TBD

Regulatory issues
TBD



CASE DISCUSSIONS


                                                                                                                        


Moderator: Mothaffar Rimawi, MD
Baylor College of Medicine
Houston, TX
              



CAREER DEVELOPMENT FORUMA NETWORKING SESSION FOR YOUNG INVESTIGATORS


                                                                                                                        


The session is open to early-career scientists, defined as graduate students, postdoctoral or clinical fellows, or medical students and residents, who are registered attendees of the 2017 SABCS. Space in the workshop is limited to 220 participants; registrations will be accepted on a first-come, first-served basis and is free of charge.                                                                                                                             



                                                                                                                

    
                                                                                                                       


Round table discussions sharing best practices and successful collaborations in research and clinical settings. This session is open to registered attendees of the 2017 SABCS. Space is limited to 80 participants; registrations will be accepted on a first-come, first-served basis and is free of charge. 



Friday, December 8, 2017
                                                                                                                       


Will examine presentations at SABCS and put them in context of clinical practice
Moderator: Lisa A. Carey, MD
University of North Carolina at Chapel Hill
Chapel Hill, NC


Panel Members

Matthew J. Ellis, MD, PHD
Baylor College of Medicine
Houston, TX

Susan G. Hilsenbeck, PhD
Baylor College of Medicine
Houston, TX

Patricia Spears, BS
University North Carolina
Lineberger Comprehensive Cancer Center
Chapel Hill, NC

Steven E. Vogl, MD
Montefiore Medical Center
Bronx, NY

Eric P. Winer, MD
Dana-Farber Cancer Institute
Boston, MA

      

.

Top

PRELIMINARY SCHEDULE

Hours subject to change

Tuesday, December 5
Registration
8:00 AM-7:00 PM
Program (Educational Sessions)
11:00 AM-7:00 PM
Wednesday, December 6
Registration
7:00 AM-5:15 PM
Program (Main Program begins)
8:00 AM-7:00 PM
Exhibits
11:00 AM-5:00 PM
Thursday, December 7
Registration
7:00 AM-5:15 PM
Program
7:30 AM-7:00 PM
Exhibits
11:00 AM-5:00 PM
Friday, December 8
Registration
7:00 AM-5:15 PM
Program
7:30 AM-7:00 PM
Exhibits
11:00 AM-5:00 PM
 
Saturday, December 9
Registration
7:00 AM-9:00 AM
Program
7:30 AM-11:00 AM
Top